LENZ Therapeutics, Inc. (LENZ)
| Market Cap | 182.24M -83.5% |
| Revenue (ttm) | 21.48M +329.5% |
| Net Income | -126.00M |
| EPS | -4.12 |
| Shares Out | 31.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 910,934 |
| Open | 5.21 |
| Previous Close | 5.23 |
| Day's Range | 5.21 - 5.81 |
| 52-Week Range | 4.54 - 50.40 |
| Beta | 1.63 |
| Analysts | Buy |
| Price Target | 24.00 (+313.79%) |
| Earnings Date | Aug 11, 2026 |
About LENZ
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LENZ stock is "Buy." The 12-month stock price target is $24.0, which is an increase of 313.79% from the latest price.
News
Lenz Therapeutics reports Q2 EPS ($1.02), consensus ($1.07)
Reports Q2 revenue $5.49M, consensus $2.38M. “We are encouraged by the early refill behavior we are seeing with VIZZ. The majority of ePharmacy patients have purchased multiple monthly packs since…
Lenz Therapeutics price target lowered to $10 from $20 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Lenz Therapeutics (LENZ) to $10 from $20 and keeps a Buy rating on the shares post the Q2 report. The…
Lenz Therapeutics price target lowered to $7 from $12 at Piper Sandler
Piper Sandler lowered the firm’s price target on Lenz Therapeutics (LENZ) to $7 from $12 and keeps a Neutral rating on the shares following quarterly results. The firm cites lower…
Lenz Therapeutics downgraded to Neutral from Buy at BofA
BofA downgraded Lenz Therapeutics (LENZ) to Neutral from Buy with a price target of $7, down from $31, citing a slower-than-expected VIZZ presbyopia launch. Lenz remains a single-product biotech focus...
LENZ Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw modest growth, with July prescriptions up over 45% after telehealth and TV campaign launches. Strong patient persistence and global expansion underpin confidence, while disciplined capital allocation and high refill rates distinguish VIZZ in the market.
LENZ Therapeutics Earnings release: Q2 2026
LENZ Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
LENZ Therapeutics Quarterly report: Q2 2026
LENZ Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple ...
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmo...
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) today announced an exclusive license and c...
Lenz announces Everest Medicines acquired rights to develop VIZZ in China
LENZ Therapeutics (LENZ) announced that Everest Medicines has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals to acquire the rights to develop, manufacture, and commercialize VIZZ...
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 The New Drug Application for LNZ100 in China was submitted September 2025 with approval a...
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmol...
Lenz Therapeutics price target lowered to $20 from $26 at Citi
Citi lowered the firm’s price target on Lenz Therapeutics (LENZ) to $20 from $26 and keeps a Buy rating on the shares.
LENZ Therapeutics trading halted, volatility trading pause
09:33 EDT LENZ Therapeutics (LENZ) trading halted, volatility trading pause
LENZ Therapeutics trading resumes
09:38 EDT LENZ Therapeutics (LENZ) trading resumes
Lenz Therapeutics price target raised to $31 from $29 at BofA
BofA raised the firm’s price target on Lenz Therapeutics (LENZ) to $31 from $29 and keeps a Buy rating on the shares. The firm remains “optimistic” on VIZZ launch efforts…
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Lenz Therapeutics (LENZ) to $38 from $48 and keeps a Buy rating on the shares. The firm reduced its…
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Lenz Therapeutics (LENZ) to Neutral from Overweight with a price target of $12, down from $39, following the Q1 report. The company’s pace of new patient starts…
Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)
Reports Q1 revenue $1.9M, consensus $1.76M. “We have made significant progress in the early quarters of launch driving high ECP awareness, growing prescriber experience and confidence with VIZZ, and h...
LENZ Therapeutics Earnings Call Transcript: Q1 2026
Q1 saw 25,000 prescriptions and $1.9M in net revenue, with strong early refill trends and over 10,000 prescribers. SG&A rose due to DTC investment, but cash remains strong. Focus is on accelerating adoption, expanding globally, and maintaining a favorable safety profile.
LENZ Therapeutics Earnings release: Q1 2026
LENZ Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
LENZ Therapeutics Quarterly report: Q1 2026
LENZ Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch throu...